Skip to main content
Barbara L. Banbury on Muck Rack

Barbara L. Banbury

As seen in: Nature, Cancer Epidemiology, Biomarkers & Prevention, Gastroenterology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Barbara L.

Contact Barbara L., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Potent and dose-sparing next-generation SARS-CoV-2 vaccine, mRNA-1283, induces polyfunctional and durable T cell immunity - npj Vaccines

|
By Yamuna D Paila, Rolando Pajon, Barbara L. Banbury, Paul Fields, Maha Maglinao, Stephen De Rosa, Daryl Morris, M. Juliana McElrath, Uma Siangphoe, Kristen Cohen, Robert M. Paris
| Nature Verified
Abstract Cell-mediated immunity contributes to durable protection against severe COVID-19, particularly as antibody responses wane or viral variants partially evade neutralization. Here, we characterize SARS-CoV-2-specific T cell responses elicited by a next-generation COVID-19 vaccine, mRNA-1283, which encodes the receptor-binding and N-terminal domains of the spike protein, in a phase 1 randomized clinical trial (NCT04813796).
Open in Who Shared Issue with article?

CEI: A Clonal Expansion Identifier for T-cell receptor clones following SARS-CoV-2 vaccination

|
By Christian Hofmann, Barbara L. Banbury, Stephanie A. Bien, Tom Chou
| arxiv.org
arXivLabs is a framework that allows collaborators to develop and share new arXiv features directly on our website. Both individuals and organizations that work with arXivLabs have embraced and accepted our values of openness, community, excellence, and user data privacy. arXiv is committed to these values and only works with partners that adhere to them. Have an idea for a project that will add value for arXiv's community? Learn more about arXivLabs.
Open in Who Shared View Duplicates (630) Issue with article?

Neoadjuvant or concurrent atezolizumab with chemoradiation for locally advanced cervical cancer: a randomized phase I trial - Nature Communications

|
By Jyoti S. Mayadev, Dmitriy Zamarin, Heather A. Lankes, Barbara L. Banbury, Cara Mathews, David M. O’Malley, Roisin E. O’Cearbhaill
| Nature Verified
Abstract Combined immune checkpoint blockade (ICB) and chemoradiation (CRT) is approved in patients with locally advanced cervical cancer (LACC) but optimal sequencing of CRT and ICB is unknown. NRG-GY017 (NCT03738228) was a randomized phase I trial of atezolizumab (anti-PD-L1) neoadjuvant and concurrent with CRT (Arm A) vs. concurrent with CRT (Arm B) in patients with high-risk node-positive LACC.
Open in Who Shared Issue with article?
See all 10 articles